Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Probiotics  COVID-19 treatment studies for Probiotics  C19 studies: Probiotics  Probiotics   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 62% Improvement Relative Risk ICU admission 0% Di Pierro et al. NCT05043376 Probiotics RCT LATE Is late treatment with probiotics beneficial for COVID-19? RCT 50 patients in Pakistan (August - November 2021) Lower mortality with probiotics (not stat. sig., p=0.17) Di Pierro et al., Microorganisms, doi:10.3390/microorganisms10101926 Favors probiotics Favors control
Clinical Effects of Streptococcus salivarius K12 in Hospitalized COVID-19 Patients: Results of a Preliminary Study
Di Pierro et al., Microorganisms, doi:10.3390/microorganisms10101926, NCT05043376 (history)
Di Pierro et al., Clinical Effects of Streptococcus salivarius K12 in Hospitalized COVID-19 Patients: Results of a Preliminary.., Microorganisms, doi:10.3390/microorganisms10101926, NCT05043376
Sep 2022   Source   PDF  
  All Studies   Meta
RCT 50 hospitalized patients in Pakistan, 25 treated with S. salivarius K12, showing lower mortality with treatment, without statistical significance. There were more patients with higher oxygen requirements at baseline in the control group - 18 vs. 6 with O2 ≥ 8 L/min.
The immune effects of probiotics are strain-specific. This study is excluded in the after exclusion results of meta analysis: unadjusted differences between groups.
risk of death, 62.5% lower, RR 0.38, p = 0.17, treatment 3 of 25 (12.0%), control 8 of 25 (32.0%), NNT 5.0.
risk of ICU admission, no change, RR 1.00, p = 1.00, treatment 8 of 25 (32.0%), control 8 of 25 (32.0%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Di Pierro et al., 28 Sep 2022, Randomized Controlled Trial, Pakistan, peer-reviewed, mean age 48.5, 7 authors, study period 11 August, 2021 - 18 November, 2021, trial NCT05043376 (history).
Contact: (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperProbioticsAll
Abstract: microorganisms Article Clinical Effects of Streptococcus salivarius K12 in Hospitalized COVID-19 Patients: Results of a Preliminary Study Francesco Di Pierro 1,2, * , Somia Iqtadar 3 , Sami Ullah Mumtaz 3 , Alexander Bertuccioli 4 , Martino Recchia 5 , Nicola Zerbinati 6 and Amjad Khan 7 1 2 3 4 5 6 7 * Scientific & Research Department, Velleja Research, 20100 Milan, Italy Digestive Endoscopy, Fondazione Poliambulanza, 25133 Brescia, Italy Department of Medicine, King Edward Medical University, Lahore 54000, Pakistan Department of Biomolecular Sciences (DISB), University of Urbino, 61029 Urbino, Italy Medistat, Unità di Epidemiologia Clinica e Biostatistica, 20100 Milan, Italy Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy Nuffield Division of Clinical and Laboratory Sciences (NDCLS), Radcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK Correspondence:; Tel.: +39-0523-510848; Fax: +39-0523-511894 Academic Editor: Despoina Koulenti Abstract: Anatomical and physiological considerations indicate that the oral cavity is a primary source of the lung microbiota community, and recent studies have shown that the microbiota in the lungs contributes to immunological homeostasis, potentially altering the organ’s susceptibility to viral infection, including SARS-CoV-2. It has been proposed that, in the case of viral infection, lung Gram-negative bacteria could promote the cytokine cascade with a better performance than a microbiota mainly constituted by Gram-positive bacteria. Recent observations also suggest that Prevotella-rich oral microbiotas would dominate the oral cavity of SARS-CoV-2-infected patients. In comparison, Streptococcus-rich microbiotas would dominate the oral cavity of healthy people. To verify if the modulation of the oral microbiota could have an impact on the current coronavirus disease, we administered for 14 days a well-recognized and oral-colonizing probiotic (S. salivarius K12) to hospitalized COVID-19 patients. The preliminary results of our randomized and controlled trial seem to prove the potential role of this oral strain in improving the course of the main markers of pathology, as well as its ability to apparently reduce the death rate from COVID-19. Although in a preliminary and only circumstantial way, our results seem to confirm the hypothesis of a direct involvement of the oral microbiota in the construction of a lung microbiota whose taxonomic structure could modulate the inflammatory processes generated at the pulmonary and systemic level by a viral infection. Received: 27 August 2022 Keywords: oral microbiota; lantibiotics; salivaricins; Streptococcus salivarius; COVID-19; SARS-CoV-2 Citation: Di Pierro, F.; Iqtadar, S.; Mumtaz, S.U.; Bertuccioli, A.; Recchia, M.; Zerbinati, N.; Khan, A. Clinical Effects of Streptococcus salivarius K12 in Hospitalized COVID-19 Patients: Results of a Preliminary Study. Microorganisms 2022, 10, 1926. 10.3390/microorganisms10101926 Accepted: 24 September 2022 Published: 28 September 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop